The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday brought 60 of its member companies’ researchers to Capitol Hill for meetings with members of Congress.
Specialty Pharmacy News
Both the Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization issues statements in support of the letter.
According to the report, some 311 medicines and vaccines for autoimmune diseases are either in clinical trials or awaiting Food and Drug Administration approval.
“We are excited to welcome Excelera members into NASP and important conversations around appropriate access to specialty medications and related services,” NASP membership committee chair Mike Agostino said
"We think Kroger is going to be a winner in the health and wellness market, and we are excited to see what they build from this point forward," commented Casey Lynch, Altamont managing director.
The company is encouraging people to share their stories about experiences with cancer — either their personal experience or that of someone they know — using the hashtag #CancerTaughtMe.
Pharmacy technology company ScriptPro is positioning itself as a provider of solutions that will ease common pain points that come with increased script volume and the influx of paperwork from clinical services with two forthcoming innovations that address pharmacy documentation needs and the will-call process.
The acquisition saw Allergan pay RetroSense Therapeutics a $60 million upfront payment, with the promise of potential regulatory and commercialization milestone payments for the company’s lead development program, RST-001 — a potential therapy for retinitis pigmentosa.
Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R&D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the formulary, The National Law Review suggested. (The National Law Review)